Want to see ELVN full AI Analyst Report?
ELVN Stock Chart & Stats
$48.11
$0.01(0.04%)
At close: 4:00 PM EST
$48.11
$0.01(0.04%)
Day’s Range― - ―
52-Week Range$14.79 - $54.88
Previous CloseN/A
Volume37.78K
Average Volume (3M)1.91M
Market Cap
$3.88B
Enterprise Value$2.60B
Total Cash (Recent Filing)$452.40M
Total Debt (Recent Filing)$302.00K
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Aug 19, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding71,438,280
10 Day Avg. Volume886,913
30 Day Avg. Volume1,914,933
Financial Highlights & Ratios
PEG Ratio2.65
Price to Book (P/B)1.90
Price to Sales (P/S)0.00
P/FCF Ratio-12.38
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-43.34K
Enterprise Value/Ebitda-26.38
Forecast
1Y Price Target
$65.44Price Target Upside36.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Sizable Equity BaseNear-zero debt and a materially larger equity base provide durable financial flexibility for a clinical-stage biotech. This reduces solvency risk, supports multi-year R&D programs, and improves the company's ability to fund trials or withstand setbacks without immediate liquidity stress, strengthening runway for 2–6 months and beyond.
Positive ELVN-001 Phase 1 Data With FDA AlignmentRobust early efficacy and a favorable safety profile plus FDA agreement on dose and pivotal trial enrollment meaningfully lower regulatory and development execution risk. Dose selection and Phase 3 alignment improve predictability of the pathway to approval and support durable clinical value creation if results hold in the pivotal setting.
Successful Upsized Equity Raise To Fund PipelineAccess to a large, recent equity raise demonstrates market financing capacity and materially extends funding runway for late-stage studies. This reduces near-term liquidity risk, enabling enrollment and regulatory activities for ELVN-001 and other programs without immediate cutbacks to development plans.
Bears Say
Pre-revenue With Widening Operating LossesSustained, widening operating losses reflect the intrinsic risk of a clinical-stage model: no product revenue yet and large R&D-driven deficits. Continued losses constrain the path to profitability, increase dependency on external funding, and mean equity capital must generate future returns to justify today’s investment.
Persistent Negative Operating And Free Cash FlowRepeated negative cash generation forces recurrent capital raises and limits optionality. Even with recent financing, ongoing burn means the company will likely need more funding to complete pivotal trials, exposing operations to market funding cycles and potential program delays if liquidity tightens.
Dilution Risk From Share Authorization And Equity OfferingExpanded share authorization plus a large primary offering increase the risk of shareholder dilution and lower per-share economic interest for existing holders. Repeated dilution can compress long-term per-share returns even if the programs succeed, and it alters capital structure dynamics for future strategic options.
Enliven Therapeutics News
ELVN FAQ
What was Enliven Therapeutics, Inc.’s price range in the past 12 months?
Enliven Therapeutics, Inc. lowest stock price was $14.79 and its highest was $54.88 in the past 12 months.
What is Enliven Therapeutics, Inc.’s market cap?
Enliven Therapeutics, Inc.’s market cap is $3.88B.
When is Enliven Therapeutics, Inc.’s upcoming earnings report date?
Enliven Therapeutics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 27 days.
How were Enliven Therapeutics, Inc.’s earnings last quarter?
Enliven Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.444 by $0.064.
Is Enliven Therapeutics, Inc. overvalued?
According to Wall Street analysts Enliven Therapeutics, Inc.’s price is currently Undervalued.
Does Enliven Therapeutics, Inc. pay dividends?
Enliven Therapeutics, Inc. does not currently pay dividends.
What is Enliven Therapeutics, Inc.’s EPS estimate?
Enliven Therapeutics, Inc.’s EPS estimate is -0.39.
How many shares outstanding does Enliven Therapeutics, Inc. have?
Enliven Therapeutics, Inc. has 71,438,280 shares outstanding.
What happened to Enliven Therapeutics, Inc.’s price movement after its last earnings report?
Enliven Therapeutics, Inc. reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.444. Following the earnings report the stock price went up 1.142%.
Which hedge fund is a major shareholder of Enliven Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ELVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enliven Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.44 (36.03% Upside)
$65.44 (36.03% Upside)
Blogger Sentiment
Bearish
ELVN Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $51.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.4%
Last 30 Days ▲ 18.7%
Last 30 Days ▲ 18.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
148.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
53.63%
Trailing 12-Months
Company Description
Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
ELVN Stock 12 Month Forecast
Average Price Target
$65.44
▲(36.03% Upside)
Technical Analysis
Sarepta Therapeutics
―
Viridian Therapeutics
―
―
Intellia Therapeutics
―
AbCellera Biologics
―
Ownership Overview
23.09% Insiders
14.26% Mutual Funds
0.60% Other Institutional Investors
52.30% Public Companies and
Individual Investors